Can Zelnorm compete in IBS-C a decade after recall? by Kyle Blankenship Tuesday, September 17, 2019 Novartis' Zelnorm was a steady seller before safety flags pushed it off the market. Now—more than a decade later—can its new owners mount a comeback?
